A detailed history of Ifp Advisors, Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 530 shares of VKTX stock, worth $22,392. This represents 0.0% of its overall portfolio holdings.

Number of Shares
530
Holding current value
$22,392
% of portfolio
0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$47.39 - $80.2 $25,116 - $42,506
530 New
530 $28,000
Q2 2022

Sep 06, 2022

BUY
$2.11 - $3.15 $877 - $1,310
416 New
416 $4,000
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $877 - $1,310
-416 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$3.0 - $4.88 $1,200 - $1,952
400 Added 2500.0%
416 $1,000
Q4 2021

Jan 12, 2022

SELL
$4.6 - $6.72 $13,284 - $19,407
-2,888 Reduced 99.45%
16 $1,000
Q3 2021

Oct 06, 2021

BUY
$5.58 - $7.04 $167 - $211
30 Added 1.04%
2,904 $32,000
Q2 2021

Jul 13, 2021

SELL
$5.19 - $6.73 $93 - $121
-18 Reduced 0.62%
2,874 $15,000
Q1 2021

Apr 30, 2021

BUY
$5.74 - $9.67 $2,186 - $3,684
381 Added 15.17%
2,892 $16,000
Q4 2020

Jan 25, 2021

SELL
$5.3 - $6.71 $190 - $241
-36 Reduced 1.41%
2,511 $13,000
Q1 2020

May 12, 2020

SELL
$3.45 - $7.95 $2,190 - $5,048
-635 Reduced 19.96%
2,547 $12,000
Q4 2019

Jan 17, 2020

BUY
$6.38 - $8.73 $338 - $462
53 Added 1.69%
3,182 $27,000
Q3 2019

Nov 07, 2019

BUY
$6.55 - $8.6 $16,564 - $21,749
2,529 Added 421.5%
3,129 $21,000
Q1 2019

May 15, 2019

SELL
$7.58 - $9.94 $19,389 - $25,426
-2,558 Reduced 81.0%
600 $6,000
Q4 2018

Jan 23, 2019

BUY
$7.16 - $16.21 $18,315 - $41,465
2,558 Added 426.33%
3,158 $24,000
Q3 2018

Oct 25, 2018

SELL
$9.7 - $19.65 $38,800 - $78,600
-4,000 Reduced 86.96%
600 $0
Q2 2018

Aug 07, 2018

BUY
$3.88 - $12.74 $14,453 - $47,456
3,725 Added 425.71%
4,600 $0
Q1 2018

May 09, 2018

BUY
$4.11 - $6.93 $1,130 - $1,905
275 Added 45.83%
875 $0
Q1 2016

Jun 03, 2019

BUY
N/A
600
600 $6,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.24B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.